α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Neuropharmacology

• Publication date

  2013-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.neuropharm.2013.03.038PMID 23583932PMCID PMC3685407
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function.

  2013cited by this paper
• Striatal plasticity in Parkinson's disease and L-dopa induced dyskinesia.

  2012cited by this paper
• Effects of sazetidine-A, a selective α4β2* nicotinic receptor desensitizing agent, on body temperature regulation in mice and rats.

  2012cited by this paper
• Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease.

  2012cited by this paper
• Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice.

  2012cited by this paper
• New pharmacological avenues for the treatment of l-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors

  2012cited by this paper
• Role of alpha6 nicotinic receptors in CNS dopaminergic function; relevance to addiction and neurological disorders

  2012cited by this paper
• Chronic Sazetidine-A at Behaviorally Active Doses Does Not Increase Nicotinic Cholinergic Receptors in Rodent Brain

  2012cited by this paper
• An autoradiographic survey of mouse brain nicotinic acetylcholine receptors defined by null mutants.

  2011cited by this paper
• Milestones in Parkinson's disease therapeutics

  2011cited by this paper
• α4β2 Nicotinic Receptors Partially Mediate Anti-Inflammatory Effects through Janus Kinase 2-Signal Transducer and Activator of Transcription 3 but Not Calcium or cAMP Signaling

  2011cited by this paper
• Varenicline Is a Potent Agonist of the Human 5-Hydroxytryptamine3 Receptor

  2011cited by this paper
• α6β2* and α4β2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson's Disease

  2011cited by this paper
• Progress and challenges in the study of α6-containing nicotinic acetylcholine receptors.

  2011cited by this paper
• Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia.

  2011influential reference
• Modulation of striatal projection systems by dopamine.

  2011cited by this paper
• Molecular mechanisms of l-DOPA-induced dyskinesia.

  2011cited by this paper
• Priorities in Parkinson's disease research

  2011cited by this paper
• Etiology and pathogenesis of Parkinson's disease

  2011cited by this paper
• Consensus Paper: Roles of the Cerebellum in Motor Control—The Diversity of Ideas on Cerebellar Involvement in Movement

  2011cited by this paper
• Anatomically Selective Serotonergic Type 1A and Serotonergic Type 2A Therapies for Parkinson's Disease: An Approach to Reducing Dyskinesia without Exacerbating Parkinsonism?

  2011cited by this paper
• Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation

  2011influential reference
• Desensitization of δ-opioid receptors in nucleus accumbens during nicotine withdrawal

  2011cited by this paper
• Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.

  2011cited by this paper
• Nicotine Reduces l-DOPA-Induced Dyskinesias by Acting at β2* Nicotinic Receptors

  2011cited by this paper
• Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders.

  2011cited by this paper
• Stimulating Nicotinic Receptors Trigger Multiple Pathways Attenuating Cytotoxicity in Models of Alzheimer's and Parkinson's Diseases

  2011cited by this paper
• New approaches to therapy.

  2011cited by this paper
• Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease.

  2011cited by this paper
• Nicotine Reduces L -DOPA-Induced Dyskinesias by Acting at (cid:1) 2* Nicotinic Receptors

  2011influential reference
• Nicotinic Receptor-Mediated Reduction in l-DOPA-Induced Dyskinesias May Occur via Desensitization

  2010cited by this paper
• Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.

  2010cited by this paper
• Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.

  2010cited by this paper
• Pre‐clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence

  2010cited by this paper
• Missing pieces in the Parkinson's disease puzzle

  2010cited by this paper
• Effect of the alpha4beta2* nicotinic acetylcholine receptor partial agonist varenicline on dopamine release in beta2 knock-out mice with selective re-expression of the beta2 subunit in the ventral tegmental area.

  2010cited by this paper
• A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.

  2010cited by this paper
• Diversity of vertebrate nicotinic acetylcholine receptors.

  2009influential reference
• The role of the dorsal raphe nucleus in the development, expression, and treatment of L‐dopa‐induced dyskinesia in hemiparkinsonian rats

  2009cited by this paper
• Structural and functional diversity of native brain neuronal nicotinic receptors.

  2009influential reference
• Desensitization of Nicotinic Acetylcholine Receptors as a Strategy for Drug Development

  2009cited by this paper
• Mammalian nicotinic acetylcholine receptors: from structure to function.

  2009influential reference
• The cortico-basal ganglia integrative network: the role of the thalamus.

  2009cited by this paper
• Mouse Striatal Dopamine Nerve Terminals Express α4α5β2 and Two Stoichiometric Forms of α4β2*-Nicotinic Acetylcholine Receptors

  2009cited by this paper
• Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models.

  2009cited by this paper
• Continuous and Intermittent Nicotine Treatment Reduces l-3,4-Dihydroxyphenylalanine (l-DOPA)-Induced Dyskinesias in a Rat Model of Parkinson's Disease

  2008cited by this paper
• Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.

  2008cited by this paper
• Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: potential targets for the development of new therapeutic agents.

  2008cited by this paper
• Molecular mechanisms of L-DOPA-induced dyskinesia

  2008cited by this paper
• Sazetidine-A Is a Potent and Selective Agonist at Native and Recombinant α4β2 Nicotinic Acetylcholine Receptors

  2008influential reference
• It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood.

  2008cited by this paper
• Involvement of the serotonin system in L-dopa-induced dyskinesias.

  2008cited by this paper
• Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias.

  2008cited by this paper
• Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease.

  2008cited by this paper
• Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease

  2008cited by this paper
• New approaches to therapy

  2007influential reference
• Nicotine reduces levodopa‐induced dyskinesias in lesioned monkeys

  2007cited by this paper
• Ratings of L‐DOPA‐Induced Dyskinesia in the Unilateral 6‐OHDA Lesion Model of Parkinson's Disease in Rats and Mice

  2007influential reference
• The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.

  2007cited by this paper
• Advances in understanding L-DOPA-induced dyskinesia.

  2007cited by this paper
• Role of striatal l‐DOPA in the production of dyskinesia in 6‐hydroxydopamine lesioned rats

  2006cited by this paper
• Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms

  2006cited by this paper
• Involvement of Sensorimotor, Limbic, and Associative Basal Ganglia Domains in L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia

  2005cited by this paper
• [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].

  2004cited by this paper
• Parkinson’s disease: Is the initial treatment established?

  2003cited by this paper
• Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice.

  2003cited by this paper
• Animal models of neurological deficits: how relevant is the rat?

  2002cited by this paper
• Identification of the Nicotinic Receptor Subtypes Expressed on Dopaminergic Terminals in the Rat Striatum

  2002cited by this paper
• Forced Nonuse in Unilateral Parkinsonian Rats Exacerbates Injury

  2002cited by this paper
• Declines in Different β2* Nicotinic Receptor Populations in Monkey Striatum after Nigrostriatal Damage

  2002cited by this paper
• Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies

  2001cited by this paper
• Vulnerability of 125I-α-Conotoxin MII Binding Sites to Nigrostriatal Damage in Monkey

  2001cited by this paper
• CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury.

  2000cited by this paper
• α-Bungarotoxin-Sensitive Nicotinic Receptors Indirectly Modulate [3H]Dopamine Release in Rat Striatal Slices via Glutamate Release

  2000cited by this paper
• Levodopa motor complications in Parkinson's disease.

  2000cited by this paper
• Characterisation of the binding of [3H]methyllycaconitine: a new radioligand for labelling alpha 7-type neuronal nicotinic acetylcholine receptors.

  1999cited by this paper
• The heterocyclic substituted pyridine derivative (+/-)-2-(-3-pyridinyl)-1-azabicyclo[2.2.2]octane (RJR-2429): a selective ligand at nicotinic acetylcholine receptors.

  1998cited by this paper
• L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNA

  1998cited by this paper
• The use of 3H standards in 125I autoradiography.

  1990cited by this paper
• Compensations after lesions of central dopaminergic neurons: some clinical and basic implications.

  1990cited by this paper
• The binding of L-[3H]nicotine to a single class of high affinity sites in rat brain membranes.

  1986cited by this paper
• Author's Personal Copy Behavioural Brain Research Parallel Contributions of Cerebellar, Striatal and M1 Mechanisms to Motor Sequence Learning

  year unknowncited by this paper

• Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression

  2025cites this paper
• The Role of α7-Nicotinic Acetylcholine Receptors in the Pathophysiology and Treatment of Parkinson’s Disease

  2025cites this paper
• Central cholinergic transmission modulates endocannabinoid-induced marble-burying behavior in mice.

  2024cites this paper
• Neuroplasticity in levodopa-induced dyskinesias: an overview on pathophysiology and therapeutic targets.

  2023cites this paper
• Central cholinergic transmission affects the compulsive-like behavior of mice in marble-burying test.

  2023cites this paper
• Striatal synaptic adaptations in Parkinson’s disease

  2022cites this paper
• A molecular docking-based comparative assessment of various anticholinergic drugs as antidotes to different nerve agent poisoning

  2022cites this paper
• Memantine has a nicotinic neuroprotective pathway in acute hippocampal slices after an NMDA insult

  2022cites this paper
• Leveraging VGLUT3 Functions to Untangle Brain Dysfunctions.

  2021cites this paper
• Allosterism of Nicotinic Acetylcholine Receptors: Therapeutic Potential for Neuroinflammation Underlying Brain Trauma and Degenerative Disorders

  2020cites this paper
• Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease

  2019cites this paper
• α7-Nicotinic acetylcholine receptor antagonist QND7 suppresses non-small cell lung cancer cell proliferation and migration via inhibition of Akt/mTOR signaling.

  2019cites this paper
• Nicotinic acetylcholine receptors in experimental models of Parkinson’s disease and levodopa-induced dyskinesia : focus on α5 subunit-containing receptors

  2019cites this paper
• Genetic Knockdown of mGluR5 in Striatal D1R-Containing Neurons Attenuates l-DOPA-Induced Dyskinesia in Aphakia Mice

  2018cites this paper
• A new outlook on cholinergic interneurons in Parkinson's disease and L-DOPA-induced dyskinesia.

  2018cites this paper
• The striatal cholinergic system in l-dopa-induced dyskinesias

  2018cites this paper
• Cholinergic control of striatal neurons to modulate L‐dopa‐induced dyskinesias

  2018cites this paper
• Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.

  2018cites this paper
• The Role of Human α7-Nicotinic Acetylcholine Receptors in Mediating Neuroprotective Action of Curcumin

  2018cites this paper
• Striatal cholinergic interneurons and Parkinson's disease

  2018cites this paper
• Attenuation of Compulsive-Like Behavior Through Positive Allosteric Modulation of α4β2 Nicotinic Acetylcholine Receptors in Non-Induced Compulsive-Like Mice

  2017cites this paper
• Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice

  2017cites this paper
• Determining face, predictive, construct validity and novel receptor targets in a spontaneous compulsive-like mouse model

  2017cites this paper
• The Effect of Ghrelin Agonist, Exercise, and Nicotine on Catalepsy in an Animal Model of Parkinson's Disease

  2017cites this paper
• Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias.

  2016cites this paper
• Prior nicotine self-administration attenuates subsequent dopaminergic deficits of methamphetamine in rats: role of nicotinic acetylcholine receptors

  2016cites this paper
• Molecular basis of reactive oxygen species-induced inactivation of α4β2 nicotinic acetylcholine receptors.

  2016cites this paper
• LEVODOPAN AIHEUTTAMIEN DYSKINESIOIDEN NYKYISET JA KEHITTEILLÄ OLEVAT HOITOMUODOT

  2016cites this paper
• Mechanisms of Inhibition and Potentiation of α4β2 Nicotinic Acetylcholine Receptors by Members of the Ly6 Protein Family*

  2015cites this paper
• Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson’s Disease

  2015influential citation
• Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement Disorders.

  2015cites this paper
• Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.

  2015cites this paper
• α7 nicotinic receptor agonists reduce levodopa‐induced dyskinesias with severe nigrostriatal damage

  2015cites this paper
• In vitro and in vivo neuronal nicotinic receptor properties of (+)- and (-)-pyrido[3,4]homotropane [(+)- and (-)-PHT]: (+)-PHT is a potent and selective full agonist at α6β2 containing neuronal nicotinic acetylcholine receptors.

  2015cites this paper
• Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.

  2015cites this paper
• Nicotinic Receptors

  2014cites this paper
• Nicotinic Acetylcholine Receptors in Alzheimer’s and Parkinson’s Disease

  2014cites this paper
• The α7 Nicotinic Receptor Agonist ABT-107 Decreases l-Dopa–Induced Dyskinesias in Parkinsonian Monkeys

  2014influential citation
• Identification and pharmacological characterization of 3,6-diazabicyclo[3.1.1]heptane-3-carboxamides as novel ligands for the α4β2 and α6/α3β2β3 nicotinic acetylcholine receptors (nAChRs).

  2014cites this paper
• AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.

  2014cites this paper
• Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.

  2014cites this paper
• ABT‐089 and ABT‐894 reduce levodopa‐induced dyskinesias in a monkey model of Parkinson's disease

  2014cites this paper
• Effect of nicotine on l-dopa-induced dyskinesia in animal models of Parkinson’s disease: a systematic review and meta-analysis

  2014cites this paper
• Effect of nicotine on L-dopa-induced dyskinesia in animal models of Parkinson's disease: a systematic review and meta-analysis

  2014cites this paper
• Involvement of the Cholinergic System in Levodopa-Induced Dyskinesia

  2014cites this paper
• Comparative Study on the Use of Docking and Bayesian Categorization To Predict Ligand Binding to Nicotinic Acetylcholine Receptors (nAChRs) Subtypes

  2013cites this paper
• Nicotinic Receptor Agonists Reduce l-DOPA–Induced Dyskinesias in a Monkey Model of Parkinson's Disease

  2013cites this paper
• Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice.

  2013cites this paper
• TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.

  2013influential citation